Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II

Area of Science:

• Oncology
• Immunology

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy.
• Key targets include PD-1 (nivolumab, pembrolizumab, cemiplimab), PD-L1 (durvalumab, avelumab, atezolizumab), and CTLA-4 (ipilimumab).

Purpose of the Study:

• To review the efficacy and safety of ICIs in various solid tumors.
• To highlight the potential for immune-mediated adverse effects (irAEs).
• To emphasize the importance of recognizing pulmonary toxicity associated with ICIs, particularly in lung cancer.

Main Methods:

• Review of clinical data and literature on ICI therapy.
• Analysis of efficacy in melanoma, lung cancer, and other solid tumors.
• Examination of safety profiles, focusing on irAEs and pulmonary toxicity.

Main Results:

• ICIs demonstrate remarkable efficacy as monotherapy or combination treatments.
• ICIs are generally well-tolerated but can induce irAEs across organ systems.
• Pulmonary toxicity is a significant irAE that requires careful diagnosis, especially in lung cancer patients.

Conclusions:

• ICIs represent a major advancement in cancer treatment with broad applicability.
• Awareness and prompt management of irAEs, particularly pulmonary toxicity, are crucial for patient safety.
• Ongoing research continues to expand ICI indications and refine treatment strategies.